Astria Therapeutics’ stockholders voted in a special meeting on January 21, 2026 to approve a merger with BioCryst Pharmaceuticals, Inc. The transaction is expected to close on or about January 23, 2026, subject to customary closing conditions.
The deal values Astria at approximately $700 million in enterprise value. Shareholders will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each Astria share, implying a purchase price of $13.00 per Astria share—an implied premium over the company’s market price at the time of the announcement.
Strategically, the merger expands BioCryst’s hereditary angioedema (HAE) portfolio by adding navenibart, a late‑stage, long‑acting plasma kallikrein inhibitor that could be administered every three to six months. BioCryst already markets Orladeyo, an oral HAE therapy, and the addition of an injectable option positions the company to serve a broader patient base. The transaction also brings Astria’s early‑stage atopic dermatitis program, STAR‑0310, into BioCryst’s pipeline; however, BioCryst has indicated it may pursue strategic alternatives for this asset rather than develop it internally.
To fund the cash portion of the consideration, BioCryst has secured a debt facility of up to $550 million from Blackstone‑managed funds. The financing arrangement provides the liquidity needed to complete the transaction while preserving BioCryst’s balance‑sheet flexibility.
Regulatory clearance was obtained when the Hart‑Scott‑Rodino Antitrust Improvements Act waiting period was terminated, removing a significant regulatory hurdle and allowing the parties to proceed with the merger without further antitrust review.
For Astria, the merger marks a transition from a pre‑revenue, high‑cash‑burn biopharma to a component of a larger, diversified organization. The deal provides Astria with additional resources, market access, and a broader platform for its pipeline, potentially accelerating the development and commercialization of its assets.
For BioCryst, the acquisition strengthens its HAE franchise and diversifies its product pipeline. The addition of navenibart complements the existing oral therapy, creating a more comprehensive treatment offering. The potential divestiture of STAR‑0310 allows BioCryst to focus capital and operational resources on its core HAE and other high‑potential programs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.